pillbase.ru

Rapiscan

Active substance: Regadenoson

regadenoson

Centralised EU authorisationActive

Marketing holder: GE Healthcare AS 

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 16
  • LEXISCAN
    INJECTION, SOLUTION · REGADENOSON .08 mg/mL
    0469-6501
    Astellas Pharma US, Inc.
  • LEXISCAN(R) (REGADENOSON)
    INJECTION, SOLUTION · REGADENOSON .08 mg/mL
    51662-1448
    HF Acquisition Co LLC, DBA HealthFirst
  • REGADENOSON
    INJECTION, SOLUTION · REGADENOSON .08 mg/mL
    16729-477
    Accord Healthcare Inc.
  • Regadenoson
    INJECTION, SOLUTION · REGADENOSON .08 mg/mL
    10135-803
    Marlex Pharmaceuticals, Inc.
  • Regadenoson
    INJECTION, SOLUTION · REGADENOSON .08 mg/mL
    83032-001
    Indies Pharma Jamaica Limited
All products in this country (16)
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-4634-7149-8996-5ee26b4ebbf6,01a1208c-e097-7639-8a19-de260a8e16c1,01a1208d-39ea-7945-8406-666a7b7ae13f,01a1208d-af97-7e36-a0b2-3a550b6ad59a,01a1208f-1460-7a68-9862-a8b903ac7afe;count=16 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/001176
Registration status
Active
ATC code
C01EB21
Sources
  • product · EMA · EMEA/H/C/001176 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/001176 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/001176 · Verified 2026-10-09